SCHEMBL8937475

SCHEMBL8937475

COc1cc(C(=O)N2CCN(C(=O)C=C(c3cccc(Cl)c3)c3cccc(Cl)c3)CC2)cc(OC)c1OC

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
CYP1A2 P05177 1/20 0.62
LMNA P02545 2/20 0.58
CYP3A4 P08684 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
POLB P06746 1/20 0.54
NPSR1 Q6W5P4 1/20 0.53
GAA P10253 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
TSHR P16473 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CDK5 Q00535 1/20 0.50
CDK5R1 Q15078 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937247 0.96 ALDH1A1 (0.58) ALDH1A1CYP1A2LMNACYP3A4CYP2C9
SCHEMBL8937245 0.96 ALDH1A1 (0.58) ALDH1A1CYP1A2LMNACYP3A4CYP2C9
SCHEMBL8937243 0.96 ALDH1A1 (0.58) ALDH1A1CYP1A2LMNACYP3A4CYP2C9
SCHEMBL8937408 0.95 ALDH1A1 (0.57) ALDH1A1CYP1A2LMNACYP3A4CYP2C9
SCHEMBL8937404 0.95 ALDH1A1 (0.57) ALDH1A1CYP1A2LMNACYP3A4CYP2C9
SCHEMBL8937411 0.95 ALDH1A1 (0.57) ALDH1A1CYP1A2LMNACYP3A4CYP2C9
SCHEMBL8937471 0.94 ALDH1A1 (0.64) ALDH1A1CYP1A2LMNACYP3A4CYP2C9
SCHEMBL8937467 0.94 ALDH1A1 (0.64) ALDH1A1CYP1A2LMNACYP3A4CYP2C9
SCHEMBL8937460 0.94 ALDH1A1 (0.64) ALDH1A1CYP1A2LMNACYP3A4CYP2C9
SCHEMBL8937353 0.91 ALDH1A1 (0.53) ALDH1A1CYP1A2LMNACYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP claimed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US claimed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP claimed
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed